@jerryPopsGerald@benjjjj4 But it's a public company. Endlessly not informing it's investors. What few are left. Which is why even after data. Stock will come back down huge
@benjjjj4@Ceazar_Black@BiotechXGuru Full enrollment is for PH3. Which means they know and fda told them another trial will he needed. Thus the manufacturing campaign and price.
@Ceazar_Black 6 more weeks till EOY.
Waiting patiently
For this
"under promise, over deliver"
What are your thoughts.
Seems silly to announce close to holidays. Which just leaves a few weeks
@Tjernlund How they have managed to blow through 140mi of investor money and brought zero drugs to market in 22years. How he had plans for presentations all next year but has not updated share holders properly in two years. Why he joined other companies boards.Started a Spac. Ignoring ALLR
$ALLR Where will we land when Data Hits.
Sure feels like they are planning for a Phase 3
A partnership would be mega.
Doesn't look like jap is buying it back so maybe odd out of req for that contract clause.
EOY is 7 weeks left. NOV is penny Stock Month. Would be fools to wait
@JapanDeepValue1@BioTechCash Exactly right. Few hund mill if they try to sell. If data was 20%odd+ eisai would have taken it back and sold at maket price which would likely be 150-300mil. They Will need fund raising and fda chat as said in interview end of 2027 at earliest.